technology

Dec 23, 2020

artificial intelligenceWhen it comes to companies and talent, an overriding issue for France is to keep hold of its homegrown fintechs and deter them from drifting overseas. Nicholas Pratt looks at how this is done.

Dec 23, 2020

DigitalizationDWS’s stake in Arabesque showed how asset management is moving towards AI-powered investing. Alex Rolandi talks to Arabesque and other AI players, such as Aberdeen Standard Investments, about heading for tomorrow’s world.

Dec 23, 2020

FundTech_Winter_2020_roundtableOur panellists revisit the subject of data and review the progress made in terms of standards, timeliness, quality and technology.

Dec 23, 2020

Virtual_realityNicholas Pratt hears from transfer agents about why they are unfairly held up as an example of the industry’s inefficiency.

Dec 22, 2020

AI_investingThe artificial intelligence tipping point for portfolio management is not here yet, but the technology’s role in emulating human investment decision-making processes is becoming more prevalent in the fund industry.

Dec 21, 2020

MiFID II, data management, EMTA digital utility has managed to lower data management costs related to MiFID II by over £100,000 (€110,000) for firms involved in the project.

Dec 17, 2020

The Australian superannuation sector has been subject to scrutiny from financial supervisors and policymakers over the past four to five years in search of changes that will improve efficiency, extend product choice and enhance the investment outcomes that these deliver to scheme members.

Dec 17, 2020

From the impact of technology to the future of investment advice, how do the Australian survey’s findings compare with the rest of the world’s?

Dec 17, 2020

The next section evaluates which companies will be the most valuable partners to asset management firms in managing business innovation and which will be the primary point of disruption to the investment funds industry.

Dec 10, 2020

biotechnology_investmentWith the Covid-19 pandemic, biotechnology and Big Pharma are back in the spotlight. Investors in life sciences are essentially backing developments that could determine the future of the human race, but what does investing in ‘cures’ mean from a cashflow point of view?

Pages